Smoking cessation by Doggrell, Sheila
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Doggrell, Sheila (2012) Smoking cessation. In Doggrell, Sheila (Ed.) Phar-
macology in One Semester.
This file was downloaded from: http://eprints.qut.edu.au/54885/
c© Copyright 2012 Sheila Doggrell
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
Creative Commons — Attribution-NonCommercial 3.0 Unported — CC BY-NC 3.0
http://creativecommons.org/licenses/by-nc/3.0/[22/10/2012 11:53:22 AM]
Attribution-NonCommercial 3.0 Unported (CC BY-NC 3.0)
This is a human-readable summary of the Legal Code (the full license).
Disclaimer
You are free:
to Share — to copy, distribute and transmit the work
to Remix — to adapt the work
Under the following conditions:
Attribution — You must attribute the work in the manner specified by the author or
licensor (but not in any way that suggests that they endorse you or your use of the work).
Noncommercial — You may not use this work for commercial purposes.
With the understanding that:
Waiver — Any of the above conditions can be waived if you get permission from the copyright holder.
Public Domain — Where the work or any of its elements is in the public domain under applicable
law, that status is in no way affected by the license.
Other Rights — In no way are any of the following rights affected by the license:
Your fair dealing or fair use rights, or other applicable copyright exceptions and limitations;
The author's moral rights;
Rights other persons may have either in the work itself or in how the work is used, such as
publicity or privacy rights.
Creative Commons — Attribution-NonCommercial 3.0 Unported — CC BY-NC 3.0
http://creativecommons.org/licenses/by-nc/3.0/[22/10/2012 11:53:22 AM]
Use this license for your own work.
This page is available in the following languages: 
Castellano Castellano (España) Català Dansk Deutsch English Esperanto français hrvatski Italiano Latviski Nederlands Norsk polski
Português Português (BR) Suomeksi svenska Ελληνικά Русский українська 語 (台 ) 
Notice — For any reuse or distribution, you must make clear to others the license terms of this work.
The best way to do this is with a link to this web page.
CHAPTER 21 
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 21.1 Epidemiology of cigarette smoking 
Cigarette smoking greatly increases the risk of cardiovascular disease.  There is an 
increased risk of heart attacks, strokes, coronary artery disease, peripheral arterial disease, 
impotence, hypertension, and heart failure.  Typically, men who smoke have a 3.5 times and 
women 4.8 times higher risk than never smokers of having a coronary event.  People who 
smoke cigarettes have a three-fold increase in risk of stroke. 
 
Cigarette smoking greatly increases the risk of cancer.  Cancers that cigarette smoking 
increases the risk include cancer of the lung, mouth, larynx, esophagus, bladder, pancreas, 
colon and cervix.  Lung cancer was almost unknown before the introduction of cigarettes.  
 
In addition to cancer, cigarette smoking causes other respiratory disorders such as COPD 
(chronic obstructive pulmonary disease), which is a combination of emphysema and 
bronchitis.  Eighty percent of cases of COPD are due to smoking cigarettes.  Cigarette 
smoking is also a cause of end-stage renal failure.  Smoking during pregnancy leads to an 
increased risk of miscarriage, and premature labor, and the infant’s risk of cot death. 
 
One of the reasons that people are encourage to give up, is that some of the effects of 
cigarette smoking are reversible.  Thus, it is never too late to quit, as 4-6 years after 
quitting, the risk of strokes, heart attacks etc are the same as for non-smokers.  Even 
those smokers who wait until they have a heart attack to quit live longer.  However, some 
effects are not reversible e.g. the lung damage associated with COPD. 
 
Smoking cigarettes is most common cause of preventable death and disease.  The World 
Health Organization estimates that 100 million people will die from tobacco-related diseases 
over the next 30 years, and this is more than from AIDS, tuberculosis, car accidents, 
homicide and suicide combined.   
 
In Australia, about half of the Aborigines smoke cigarettes and a third of all Aboriginal 
deaths are due to smoking related disease.  Smoking rates are lower for non-Aborigines in 
Australia, with about one in five smoking cigarettes.  Analysis of who is most likely to smoke 
has shown it is those with no qualifications, unemployed, or earning less than $30,000/year.  
Thus, smoking cigarettes is no longer considered glamorous.  It is not only the tobacco 
(nicotine) in cigarettes that is poisonous, as the tar and carbon monoxide produced by burning 
cigarettes is also toxic.  There is some controversy over the fact that sweeteners are added to 
cigarettes, presumably to make them more palatable, and attract younger people to smoking.   
 
 21.2 Nicotine, addiction and pharmacokinetics 
As discussed previously acetylcholine is widespread neurotransmitter in the autonomic 
nervous system and central nervous systems.  The subtypes of receptors for acetylcholine 
were initially distinguished by using nicotine and muscarinic, which stimulated different 
acetylcholine receptors with those being stimulated by nicotine becoming nicotinic receptors.  
In the periphery, the predominant effect of nicotine is to mimic the sympathetic nervous 
system.  Nicotine does this by stimulating nicotinic acetylcholine receptors on ganglionic 
cells, and hence the release of noradrenaline, and also by stimulating the adrenal medulla to 
secrete adrenaline.  The noradrenaline and adrenaline then cause an increase in heart rate, 
vasoconstriction, and a resulting increase in blood pressure.  
 
In the central nervous system, nicotine stimulates NN-receptors to increase the release of 
dopamine, which is pleasurable.  Nicotine also stimulates memory and alertness.  Nicotine 
also enhances cognitive skills requiring speed, reaction time, vigilance and work 
performance.  In high doses, nicotine causes tremors.  Initially when people try smoking, they 
feel sick, but unfortunately tolerance develops to this effect.  Nicotine causes reinforcement, 
which means the users find it pleasurable, making them wish to take again. 
 
The nicotine in cigarette smoking leads to nicotine addiction.  Probably, the best known 
characteristics of addiction are physical dependence and withdrawal, but they are not the 
main factor underlying addiction, which is psychological dependence.   
 
Physical dependence is a state that develops as a result of adaptation produced by a resetting 
of homeostatic mechanisms in response to repeated drug use.  With nicotine this will be the 
repeated stimulation of the sympathetic and central nicotinic receptors.  Withdrawal is the 
appearance of withdrawal syndrome when the repeated use of a drug is stopped.  The 
withdrawal syndrome with nicotine consists of irritability, impatience, hostility, anxiety, 
depression, difficulty in concentration, restlessness, decreased heart rate, increased appetite, 
and weight gain.  We can treat the physical dependence and withdraw but it is much harder to 
treat the psychological dependence.   
 
Psychological dependence is the main reason why people take drugs.  People smoke 
cigarettes because they find it pleasurable.  Being pleasurable makes the user wish to take the 
drug/nicotine again, and this is known as reinforcement.  The greater the reinforcement, the 
greater the abuse is.   
 
Nicotine is very addictive, the risk of addiction is measured as the number addicted to the 
number of ever use, and tobacco is the highest risk with one in three people who try it 
becoming addicted.  The risk of addiction is higher with nicotine than with heroin, where one 
in four people who try it become addicted.    
 
The term substance abuse or addiction is used to cover physical dependence and withdrawal, 
psychological dependence and reinforcement.  Off these, it is the psychological dependence 
which is the most difficult to overcome, as we have drugs to lessen the withdrawal associated 
with the physical dependence. 
 
The pharmacokinetics of nicotine when it is smoked, and when it is used as nicotine 
replacement therapy, are different.  When it is smoked, nicotine is readily absorbed from 
respiratory tract and buccal membranes, and readily crosses the blood brain barrier.  Thus, 
after inhaling nicotine, there can be a central effect in as little as 7 seconds.  The half-life of 
inhaled nicotine is 2 hours.  Nicotine is metabolized mainly in the liver, and nicotine and its 
metabolites are eliminated from kidney.  Nicotine is excreted in the milk of lactating women 
smokers, making their newborns smokers too. 
 
 21.2 Nicotine replacement therapy 
When nicotine replacement therapy is used the pharmacokinetics are different than from 
inhaled nicotine (Figure 21.1).  With smoking a cigarette, the concentrations of nicotine 
become high, and this gives the high associated with smoking cigarettes.  The most common 
form of nicotine replacement therapy is transdermal patches.  Nicotine is readily absorbed 
from the patches, but there is no immediate or great high. 
 
Figure 21.1 Pharmacokinetics of nicotine (Copyright Sheila Doggrell, QUT) 
 
When using replacement therapy to wean a person off of a drug and lessen the effects of 
withdrawal, the principle is always the same, and that is to stabilize on a fixed dose that is 
close to their abuse level, and then gradually reduce the dose.  With nicotine replacement 
therapy, smokers are usually stabilized on 30 cm
2
/15mg/day for 3 months, and then the dose 
is successively reduced.  Initially, the reduction is to 20cm
2
/10mg for 2-3 wk, and then the 
transdermal nicotine replacement is reduced to 10cm
2
/5mg for next 2-3 weeks.  Reducing the 
dose gradually reduces the severity of withdrawal from nicotine.  Unfortunately, contrary to 
instructions - 3 out of 10 continue to smoke when using patches, presumably because they 
miss the high they get from inhaling nicotine. 
 
The pharmaceutical companies promote nicotine replacement therapy as either increasing 
the quitters by 100% or doubling the number of quitters.  What does this mean? Short term 
the quit rates are higher than long term, and it is long term quitting that we need.  Clinical 
trials have shown that at one year, 5% of smokers given placebo patches have quit, and 10-
15% of smokers given nicotine patches have quit.  This means that with the use of nicotine 
replacement therapy, an extra 1 or 2 in 20 gives up smoking, whereas 17 in 20 continue to 
smoke.  Thus, nicotine replacement therapy is not very effective. 
 The latest version of nicotine replacement therapy is pre-quit nicotine patches.  This allows 
subjects to use nicotine replacement patches prior to quitting (i.e. while they are still smoking 
cigarettes).  One of the ideas behind this is that it may reduce smoking reinforcement.  When 
the subject is ready they move on to the standard nicotine replacement regimen.  This 
approach is quite new, and there is no data for 12 months, but it has been shown that with 
pre-quit, the quit rates at 6 months are doubled! Thus, the quit rates are 11% with placebo, 
and 22% with the pre-quit approach.  
 
 21.3 Varenicline 
A new drug that may be useful is varenicline (Champix).  Varenicline is a partial agonist at 
a subtype of nicotinic receptors, nicotinic α4β2 receptors.  As a partial agonist, varenicline 
exerts a lower maximum response that the endogenous ligand acetylcholine or nicotine 
(Figure 21.2).  By mimicking the effect of nicotine, varenicline is able to promote the release 
of dopamine, and prevent the cravings observed with withdrawal from smoking cigarettes.  
Partial agonists with high affinity are capable of removing agonists with less affinity from a 
receptor.  Varenicline has a higher for the nicotinic α4β2 receptors than nicotine, so will 
displace nicotine from the receptor.  This is believed to block the effect of nicotine (from 
cigarettes) to cause re-inforcement. 
 
Figure 21.2 Partial agonist varenicline (Copyright Sheila Doggrell, QUT) 
 
Varenicline is more effective than nicotine replacement therapy, giving quit rates of about 
20% at one year.   
 
Unfortunately, when varenicline was made available to large numbers of people, it was 
shown to worsen neuropsychiatric illness in some, and it is now contraindicated in subjects 
with neuropsychiatric illness.  Varenicline also comes with a warning to monitor subjects 
taking varenicline to make sure that a neuropsychiatric illness does not develop. 
 
 21.4 Bupropion 
Another agent that has been available for some time for smoking cessation is bupropion 
(Zybab).   Bupropion was developed as an anti-depressant, but was not very effective in 
depression.  Bupropion releases dopamine in the brain, and also inhibits NN receptors in 
brain, and these properties suggested that it may be useful in smoking cessation.   
 
After oral administration, the smoking cessation at one year was 11% in the placebo group 
and 22% in the bupropion group.  Bupropion may reduce the weight gain normally observed 
with smoking cessation.  Bupropion has been controversial and is now contraindicated in 
patients with epilepsy, or in those with a predisposition to seizures e.g. alcohol abusers. 
 In conclusion, we are still looking for an effective and save drug to promote smoking 
cessation. 
 
